Worldquant Millennium Advisors LLC Raises Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Worldquant Millennium Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 156.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,191 shares of the biopharmaceutical company’s stock after acquiring an additional 91,671 shares during the quarter. Worldquant Millennium Advisors LLC owned 0.12% of Alnylam Pharmaceuticals worth $35,341,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Allworth Financial LP boosted its holdings in Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 38 shares during the period. Investment Management Corp of Ontario raised its position in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock valued at $1,670,000 after purchasing an additional 40 shares during the last quarter. Nixon Peabody Trust Co. raised its position in Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $540,000 after purchasing an additional 43 shares during the last quarter. Brevan Howard Capital Management LP raised its position in Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 44 shares during the last quarter. Finally, IFP Advisors Inc raised its position in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 47 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on ALNY shares. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Stifel Nicolaus increased their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. Finally, Redburn Atlantic assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a “buy” rating and a $353.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $291.68 on Wednesday. The company has a market cap of $38.03 billion, a price-to-earnings ratio of -134.41 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The business’s fifty day simple moving average is $255.71 and its two-hundred day simple moving average is $253.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analysts’ expectations of $584.32 million. Alnylam Pharmaceuticals’s revenue was up 20.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.16) EPS. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.